Letter: propensity score-handle with care. Authors' reply

Affiliations

Comment

Tristan Townsend et al. Aliment Pharmacol Ther. 2021 Jan.

. 2021 Jan;53(2):362-363.

doi: 10.1111/apt.16211.

¹ Department of Gastroenterology, Royal Liverpool University Hospital, Liverpool, UK.

No abstract available

Comment on

Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
Townsend T, Razanskaite V, Dodd S, Storey D, Michail S, Morgan J, Davies M, Penman D, Watters C, Swaminathan M, Sabine J, Chapman A, Smith PJ, Flanagan PK, Reilly I, Bodger K, Subramanian S. Townsend T, et al. Aliment Pharmacol Ther. 2020 Oct;52(8):1341-1352. doi: 10.1111/apt.16057. Epub 2020 Sep 10. Aliment Pharmacol Ther. 2020. PMID: 32955122
Letter: propensity score-handle with care.
Macaluso FS, Orlando A. Macaluso FS, et al. Aliment Pharmacol Ther. 2021 Jan;53(2):360-361. doi: 10.1111/apt.16179. Aliment Pharmacol Ther. 2021. PMID: 33368517 No abstract available.

1. Macaluso F, Orlando A. Letter: propensity score - handle with care. Aliment Pharmacol Ther. 2021;53:360-361.
1. Townsend T, Razanskaite V, Dodd S, et al. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease. Aliment Pharmacol Ther. 2020;52:1341-1352.
1. Sands BE, Sandborn WJ, Van Assche G, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease in patients naïve to or who have failed tumor necrosis factor antagonist therapy. Inflamm Bowel Dis. 2017;23:97-106.
1. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016;375:1946-1960.
1. Roblin X, Rinaudo M, Del Tedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol. 2014;109:1250-1256.